Thus, intact TP53 function was found to be necessary to the action of BH3 mimetics, and the combination of MCL-1i and BCL-2 inhibitors may enhance long-term outcomes in aberrant-TP53 AML (156). Here, BCL2 is linked to acute myeloid leukemia.